Prostate cancer -- robotic surgery may be best option

September 8, 2011 By Jay D. Raman

Prostate cancer is a significant public health concern and cause of morbidity among men in the United States. In 2011, it is estimated that 240,890 new cases of prostate cancer will be diagnosed and almost 34,000 men will die of this malignancy. The lifetime probability of developing prostate cancer in American men is one in six. Current treatment alternatives for clinically localized prostate cancer include removal of the prostate gland, radiation to the cancerous prostate, active surveillance or other treatments (hormonal or cryotherapy).

Surgery for () involves removing the and adjacent seminal vesicles, as well as pelvic lymph nodes depending upon the patient’s risk. Surgery offers the knowledge that the cancer has been removed with confirmation by a pathologist regarding the extent of spread of disease. An open surgical approach involving a 4-5 cm incision below the belly button has historically been the gold standard therapy for the .

While outcomes following open prostatectomy are excellent, prolonged recovery and delayed convalescence is a legitimate concern for physicians and patients. With such considerations, an impetus within the surgical community has been to reduce the invasiveness of procedures without compromising on established standards of care. To that end, robotic surgery, which is performed via several tiny holes rather than one long incision, represents the newest frontier in minimally invasive surgery.

The first robotic-assisted surgery performed in 1995 utilized a robotic platform to eliminate the need for an assistant to hold the camera during laparoscopic procedures. The more contemporary da Vinci system (Intuitive Surgical, Sunnyvale, CA) represents the next evolutionary step. This system provides four arms, thereby allowing control of surgical optics, while simultaneously manipulating tiny surgical tools in its other hands. With a human surgeon at the controls, da Vinci filters out tremor, enhances precision, offers three-dimensional imaging and may eliminate some of the fatigue associated with conventional laparoscopy.

Robotics has experienced great popularity for urologic surgery; particularly for cancers of the prostate. In the 11 years since the Food and Drug Administration (FDA) approved the first robotic surgical system for conducting abdominal and pelvic surgeries, its use has skyrocketed. The da Vinci Surgical System is now used for just over 80 percent of radical prostatectomies performed annually in the United States. Based on studies to date, there is agreement that robotic surgery is superior to open surgery in terms of blood loss and length of hospital stay. Recovery time and convalescence also may be shorter following robotic surgery. However, when considering the three principle outcomes for prostate cancer surgery (cancer control, urinary control and sexual function), there is no consensus as to whether one approach is superior to another.

Improved diagnosis and evolving technology has increased the treatments available to patients diagnosed with prostate cancer. While robotic surgery presents one such therapy, the goal is to provide each patient with a treatment plan that is tailored to their overall health and specific type of cancer.

Related Stories

Recommended for you

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

Combining CAR T cells with existing immunotherapies may overcome resistance in glioblastomas

July 19, 2017
Genetically modified "hunter" T cells successfully migrated to and penetrated a deadly type of brain tumor known as glioblastoma (GBM) in a clinical trial of the new therapy, but the cells triggered an immunosuppressive tumor ...

How CD44s gives brain cancer a survival advantage

July 19, 2017
Understanding the mechanisms that give cancer cells the ability to survive and grow opens the possibility of developing improved treatments to control or cure the disease. In the case of glioblastoma multiforme, the deadliest ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.